Respiratory syncytial virus hospitalisation burden in children below 18 years in six European countries (2016-2023) pre-and post-COVID-19 pandemic




Jollivet, Ombeline; Urchueguia-Fornes, Arantxa; Chung-Delgado, Kocfa; Johannesen, Caroline Klint; Lehtonen, Toni; Gideonse, David; Cohen, Rachel A.; Kramer, Rolf; Orrico-Sanchez, Alejandro; Fischer, Thea K.; Heikkinen, Terho; Van Boven, Michiel; Nair, Harish; Campbell, Harry; Osei-Yeboah, Richard

PublisherELSEVIER SCI LTD

London

2025

International Journal of Infectious Diseases

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

INT J INFECT DIS

107903

155

9

1201-9712

1878-3511

DOIhttps://doi.org/10.1016/j.ijid.2025.107903

https://doi.org/10.1016/j.ijid.2025.107903

https://research.utu.fi/converis/portal/detail/492243327



Objectives:
Respiratory syncytial virus (RSV) is a substantial cause of hospital admission in young children and leads to seasonal pressure on pediatric emergency units in most countries. This study aims to assemble national or large-scale data on RSV hospitalisations from six European countries with a standardised approach to provide recent burden data for all children and assess changes since SARS-CoV-2's emergence.

Methods:
e analysed 2016-2023 hospital records from national registries in Denmark, England, Finland, The Netherlands, and Scotland, and from a hospital surveillance network in Spain-Valencia for children below 18 years. We considered separately RSV-coded and RSV laboratory-confirmed cases, comparing them to respiratory tract infections. We studied the temporal evolution of incidence rates and case reporting practices, comparing pre-and post-COVID-19 periods.

Results:
ost-COVID-19 observed RSV hospital burden was similar to the pre-COVID-19 one for younger children but higher for the 1-2 years, 3-4 years, and 5-17 years age groups. No change in terms of coding-neither diagnosis nor RSV-coding when RSV was laboratory-confirmed-was detected.

Conclusions:
ospital RSV burden in children is significant but currently not fully monitorable. Further efforts to harmonise coding practices both within and across countries would improve the quality of future analyses. Additional data in future seasons should complement current outcomes to inform decisions regarding RSV prevention. (c) 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking [grant agreement 101034339]. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. The funding source organised the collaboration and received the final report on the project. This manuscript only reflects the authors’ views, and the Joint Undertaking is not responsible for any use that may be made of the information it contains herein.


Last updated on 2025-05-06 at 08:25